Pub Date : 2024-07-18DOI: 10.1183/23120541.00312-2024
S. Law, G. Hardisty, J. Gillan, Nicola J Robinson, Donald J Davidson, Moira KB Whyte, Ian Dransfield, Robert D Gray
Cystic Fibrosis (CF) is characterised by inflammatory lung disease and large numbers of airways neutrophils. In health, neutrophils undergo apoptosis and removal from the airway. Since CF neutrophils are known to engage in apoptosis less efficiently, we wanted to assess whether alternative forms of neutrophil clearance such as NETosis were prominent in the CF airway.Sputum and blood were collected from 45 CF and 15 healthy control (HC) participants. Neutrophil morphology and biochemical properties were assessed in CF and HC sputum. Neutrophil Extracellular Traps (NETs) were measured by a novel histone-calprotectin ELISA. NET levels were compared to established measurements of airway inflammation. CF participants were followed up for one year and number of exacerbations recorded. Neutrophil and macrophage co-culture experiments were undertaken with cells from CF and HC.Neutrophil numbers were significantly higher in CF and associated with abnormal morphology. Several inflammatory mediators were elevated in CF sputum, as was cell-free DNA. This was highly correlated with sputum calprotectin, a known NET associated protein. Using a Histone/Calprotectin NETs ELISA, we demonstrated higher levels of NETs in the CF airway. CF participants treated with DNase had less sputum NETs, and in neutrophil/macrophage co-culture experiments, DNase effectively attenuated the pro-inflammatory potential of NETs, suggesting a previously unrecognised anti-inflammatory role for this treatment.NETs in the CF airway are associated with increased levels of inflammatory mediators and more severe lung disease. NETs effects on macrophages can be blocked by DNase, suggesting an anti-inflammatory role for this treatment in CF.
囊性纤维化（CF）的特征是肺部炎症和大量气道中性粒细胞。在健康状态下，中性粒细胞会发生凋亡并从气道中清除。众所周知，CF 中性粒细胞凋亡的效率较低，因此我们希望评估中性粒细胞清除的替代形式（如NETosis）在 CF 气道中是否突出。我们收集了 45 名 CF 患者和 15 名健康对照组（HC）患者的痰液和血液，对 CF 和 HC 痰液中的中性粒细胞形态和生化特性进行了评估。中性粒细胞胞外捕获物（NET）通过新型组蛋白-钙保护蛋白 ELISA 进行测量。NET水平与气道炎症的既定测量结果进行了比较。对 CF 参与者进行了为期一年的随访，并记录了病情恶化的次数。用来自CF和HC的细胞进行了中性粒细胞和巨噬细胞共培养实验。CF 痰中的几种炎症介质以及细胞游离 DNA 均升高。这与痰中的钙蛋白高度相关，钙蛋白是一种已知的NET相关蛋白。通过组蛋白/钙蛋白 NET 酶联免疫吸附试验，我们发现 CF 气道中的 NET 水平较高。在中性粒细胞/巨噬细胞共培养实验中，DNase 能有效减弱 NETs 的促炎潜能，这表明这种治疗方法具有以前未被发现的抗炎作用。CF 气道中的 NETs 与炎症介质水平升高和更严重的肺部疾病有关。NETs对巨噬细胞的影响可被DNase阻断，这表明这种疗法在CF中具有抗炎作用。
{"title":"Neutrophil extracellular traps are associated with airways inflammation and increased severity of lung disease in Cystic Fibrosis","authors":"S. Law, G. Hardisty, J. Gillan, Nicola J Robinson, Donald J Davidson, Moira KB Whyte, Ian Dransfield, Robert D Gray","doi":"10.1183/23120541.00312-2024","DOIUrl":"https://doi.org/10.1183/23120541.00312-2024","url":null,"abstract":"Cystic Fibrosis (CF) is characterised by inflammatory lung disease and large numbers of airways neutrophils. In health, neutrophils undergo apoptosis and removal from the airway. Since CF neutrophils are known to engage in apoptosis less efficiently, we wanted to assess whether alternative forms of neutrophil clearance such as NETosis were prominent in the CF airway.Sputum and blood were collected from 45 CF and 15 healthy control (HC) participants. Neutrophil morphology and biochemical properties were assessed in CF and HC sputum. Neutrophil Extracellular Traps (NETs) were measured by a novel histone-calprotectin ELISA. NET levels were compared to established measurements of airway inflammation. CF participants were followed up for one year and number of exacerbations recorded. Neutrophil and macrophage co-culture experiments were undertaken with cells from CF and HC.Neutrophil numbers were significantly higher in CF and associated with abnormal morphology. Several inflammatory mediators were elevated in CF sputum, as was cell-free DNA. This was highly correlated with sputum calprotectin, a known NET associated protein. Using a Histone/Calprotectin NETs ELISA, we demonstrated higher levels of NETs in the CF airway. CF participants treated with DNase had less sputum NETs, and in neutrophil/macrophage co-culture experiments, DNase effectively attenuated the pro-inflammatory potential of NETs, suggesting a previously unrecognised anti-inflammatory role for this treatment.NETs in the CF airway are associated with increased levels of inflammatory mediators and more severe lung disease. NETs effects on macrophages can be blocked by DNase, suggesting an anti-inflammatory role for this treatment in CF.","PeriodicalId":504874,"journal":{"name":"ERJ Open Research","volume":" 34","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141827829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-18DOI: 10.1183/23120541.00314-2024
Yoann Guirriec, D. Luque-Paz, Gontran Bernard, Axelle Mabo, M. Kerjouan, Cédric Ménard, Delphine Monnier, Hilario Nunes, Yurdagul Uzunhan, M. Reynaud-Gaubert, J. Bermudez, Raphaël Borie, B. Crestani, J. Traclet, L. Wémeau-Stervinou, Cécile Chenivesse, E. Gomez, G. Prévôt, Arnaud Bourdin, B. Bondue, Anne Bergeron, Vincent Cottin, Mathieu Lederlin, S. Jouneau
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease that may progress toward pulmonary fibrosis. Data about fibrosis prevalence and risk factors are lacking.In this retrospective multicentric nationwide cohort, we included patients newly diagnosed with aPAP between 2008 and 2018 in France and Belgium. Data were collected from medical record, using a standardized questionnaire.Sixty-one patients were included in the final analysis. We identified 5 patients (8%) with fibrosis on initial CT and 16 patients (26%) with fibrosis on final CT after a median time of 3.6 years. Dust exposure was associated with pulmonary fibrosis occurrence (OR=4.3; p=0.038).aPAP patients treated with whole lung lavage (WLL), rituximab, or GM-CSF therapy did not have more fibrotic evolution than patients who did not receive these treatments (n=25/45, 57%versusn=10/16, 62%, p=0.69). All-cause mortality was significantly higher in fibrotic than in non-fibrotic cases: n=4/16, 25%versusn=2/45, 4.4%, p=0.036 respectively.In our population, a quarter of aPAP patients progressed toward pulmonary fibrosis. Dust exposure seems to be an important factor associated with this complication. More studies are needed to analyse precisely the impact of dust exposure impact, especially silica, in patients with aPAP.
{"title":"Pulmonary fibrosis in patients with auto-immune pulmonary alveolar proteinosis: a retrospective nationwide cohort study","authors":"Yoann Guirriec, D. Luque-Paz, Gontran Bernard, Axelle Mabo, M. Kerjouan, Cédric Ménard, Delphine Monnier, Hilario Nunes, Yurdagul Uzunhan, M. Reynaud-Gaubert, J. Bermudez, Raphaël Borie, B. Crestani, J. Traclet, L. Wémeau-Stervinou, Cécile Chenivesse, E. Gomez, G. Prévôt, Arnaud Bourdin, B. Bondue, Anne Bergeron, Vincent Cottin, Mathieu Lederlin, S. Jouneau","doi":"10.1183/23120541.00314-2024","DOIUrl":"https://doi.org/10.1183/23120541.00314-2024","url":null,"abstract":"Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease that may progress toward pulmonary fibrosis. Data about fibrosis prevalence and risk factors are lacking.In this retrospective multicentric nationwide cohort, we included patients newly diagnosed with aPAP between 2008 and 2018 in France and Belgium. Data were collected from medical record, using a standardized questionnaire.Sixty-one patients were included in the final analysis. We identified 5 patients (8%) with fibrosis on initial CT and 16 patients (26%) with fibrosis on final CT after a median time of 3.6 years. Dust exposure was associated with pulmonary fibrosis occurrence (OR=4.3; p=0.038).aPAP patients treated with whole lung lavage (WLL), rituximab, or GM-CSF therapy did not have more fibrotic evolution than patients who did not receive these treatments (n=25/45, 57%versusn=10/16, 62%, p=0.69). All-cause mortality was significantly higher in fibrotic than in non-fibrotic cases: n=4/16, 25%versusn=2/45, 4.4%, p=0.036 respectively.In our population, a quarter of aPAP patients progressed toward pulmonary fibrosis. Dust exposure seems to be an important factor associated with this complication. More studies are needed to analyse precisely the impact of dust exposure impact, especially silica, in patients with aPAP.","PeriodicalId":504874,"journal":{"name":"ERJ Open Research","volume":" 25","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141825043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-18DOI: 10.1183/23120541.00248-2024
Min-Seok Chang, Hyun-Jung Kim, Ji-Ho Lee
Comorbidities significantly affect bronchiectasis prognosis. Depression and anxiety are frequently encountered psychological comorbidities that have the greatest impact on bronchiectasis. This review aimed to identify the prevalence of depression and anxiety and describe their implications on bronchiectasis.Three databases were searched from inception to October 2023 for studies reporting the prevalence and/or clinical implications of depression and anxiety in patients with bronchiectasis. Two independent reviewers rated the quality of the evidence presented in the studies using the risk of bias tool for prevalence studies.Of the 50 studies identified, 17 studies with 2637 patients were included. The overall risk of bias was classified as low (10 studies) or moderate (seven studies). The pooled prevalence of depression and anxiety was 31% (95% CI: 24%–38%) and 34% (95% CI: 28%–40%), respectively. Depression was significantly higher in female compared to male patients (risk difference: 10%; 95% CI: 0%–21%) and associated with bronchiectasis exacerbation (adjusted odds ratio: 1.72; 95% CI: 1.28–2.15). Depression and anxiety are closely associated with poor health-related quality of life (HRQOL). However, clinical outcomes including dyspnea symptoms, severity index, computed tomography score, lung function, and physical activity were not associated with depression or anxiety.This study revealed a high prevalence of depression and anxiety among patients with bronchiectasis. Depression was more prevalent in females and is significantly associated with bronchiectasis exacerbation. Depression and anxiety were associated with poor HRQOL.
{"title":"The prevalence and implications of depression and anxiety in patients with bronchiectasis: a systematic review and meta-analysis","authors":"Min-Seok Chang, Hyun-Jung Kim, Ji-Ho Lee","doi":"10.1183/23120541.00248-2024","DOIUrl":"https://doi.org/10.1183/23120541.00248-2024","url":null,"abstract":"Comorbidities significantly affect bronchiectasis prognosis. Depression and anxiety are frequently encountered psychological comorbidities that have the greatest impact on bronchiectasis. This review aimed to identify the prevalence of depression and anxiety and describe their implications on bronchiectasis.Three databases were searched from inception to October 2023 for studies reporting the prevalence and/or clinical implications of depression and anxiety in patients with bronchiectasis. Two independent reviewers rated the quality of the evidence presented in the studies using the risk of bias tool for prevalence studies.Of the 50 studies identified, 17 studies with 2637 patients were included. The overall risk of bias was classified as low (10 studies) or moderate (seven studies). The pooled prevalence of depression and anxiety was 31% (95% CI: 24%–38%) and 34% (95% CI: 28%–40%), respectively. Depression was significantly higher in female compared to male patients (risk difference: 10%; 95% CI: 0%–21%) and associated with bronchiectasis exacerbation (adjusted odds ratio: 1.72; 95% CI: 1.28–2.15). Depression and anxiety are closely associated with poor health-related quality of life (HRQOL). However, clinical outcomes including dyspnea symptoms, severity index, computed tomography score, lung function, and physical activity were not associated with depression or anxiety.This study revealed a high prevalence of depression and anxiety among patients with bronchiectasis. Depression was more prevalent in females and is significantly associated with bronchiectasis exacerbation. Depression and anxiety were associated with poor HRQOL.","PeriodicalId":504874,"journal":{"name":"ERJ Open Research","volume":" 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141825493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-18DOI: 10.1183/23120541.00188-2024
Michael E. Wechsler, L. Rogers, G. Canonica, Arnaud Bourdin, A. Altincatal, Megan Hardin, X. Soler, Paul J. Rowe, Y. Deniz, H. Sacks, J. Jacob-Nara
{"title":"Long-term dupilumab efficacy in type 2 asthma regardless of baseline characteristics","authors":"Michael E. Wechsler, L. Rogers, G. Canonica, Arnaud Bourdin, A. Altincatal, Megan Hardin, X. Soler, Paul J. Rowe, Y. Deniz, H. Sacks, J. Jacob-Nara","doi":"10.1183/23120541.00188-2024","DOIUrl":"https://doi.org/10.1183/23120541.00188-2024","url":null,"abstract":"","PeriodicalId":504874,"journal":{"name":"ERJ Open Research","volume":" 52","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141825437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-11DOI: 10.1183/23120541.00216-2024
Beatriz Valeiro, Esther Rodríguez, Jaume Ferrer, A. Pasarín, Jordi Ibañez, M. Ramon
Exacerbations of chronic obstructive pulmonary disease (COPD) decrease physical activity (PA). PA interventions after these events are desirable but have had mixed results. Understanding the barriers and enablers of PA may help to improve their results. We aimed to assess the barriers and enablers of PA after COPD exacerbation and its association with daily steps.Cross-sectional analysis of patients with COPD enrolled during a hospitalisation for an exacerbation. PA was measured with an accelerometer for 7 days after discharge. Patients completed an ad-hoc 6-point Likert-scale questionnaire about 13 barriers and 9 enablers of PA. We analysed the association between each item and patients’ daily step counts.46 patients with FEV1%pred (mean (sd)) of 48.6 (15.9) completed the assessments. They were 65 (10) years old, spent 8 (2) days hospitalised, and walked 5633 (3314) steps·day−1after discharge. The patients who reported “breathlessness” (median (p25-p75)) (3813 (2664–5639)versus5549 (3692–9984), p 0.034) and “low mood” (3813 (2456–5471)versus5426 (3612–8942), p 0.047) as barriers(yes (≥2/6) versus no (<2/6) responders, respectively)took statistically fewer daily steps; whereas if they considered “PA as healthy” as an enabler walked statically more (5085 (3538–8703)versus2760 (2271–5298), p 0.031).some barriers and enablers of PA reported by patients after a COPD exacerbation relate to daily steps. Assessing PA barriers and enablers could be useful to improve future PA interventions after these events.
{"title":"Barriers and enablers of physical activity and its association with daily steps after hospitalisation for a COPD exacerbation: what patients say matters","authors":"Beatriz Valeiro, Esther Rodríguez, Jaume Ferrer, A. Pasarín, Jordi Ibañez, M. Ramon","doi":"10.1183/23120541.00216-2024","DOIUrl":"https://doi.org/10.1183/23120541.00216-2024","url":null,"abstract":"Exacerbations of chronic obstructive pulmonary disease (COPD) decrease physical activity (PA). PA interventions after these events are desirable but have had mixed results. Understanding the barriers and enablers of PA may help to improve their results. We aimed to assess the barriers and enablers of PA after COPD exacerbation and its association with daily steps.Cross-sectional analysis of patients with COPD enrolled during a hospitalisation for an exacerbation. PA was measured with an accelerometer for 7 days after discharge. Patients completed an ad-hoc 6-point Likert-scale questionnaire about 13 barriers and 9 enablers of PA. We analysed the association between each item and patients’ daily step counts.46 patients with FEV1%pred (mean (sd)) of 48.6 (15.9) completed the assessments. They were 65 (10) years old, spent 8 (2) days hospitalised, and walked 5633 (3314) steps·day−1after discharge. The patients who reported “breathlessness” (median (p25-p75)) (3813 (2664–5639)versus5549 (3692–9984), p 0.034) and “low mood” (3813 (2456–5471)versus5426 (3612–8942), p 0.047) as barriers(yes (≥2/6) versus no (<2/6) responders, respectively)took statistically fewer daily steps; whereas if they considered “PA as healthy” as an enabler walked statically more (5085 (3538–8703)versus2760 (2271–5298), p 0.031).some barriers and enablers of PA reported by patients after a COPD exacerbation relate to daily steps. Assessing PA barriers and enablers could be useful to improve future PA interventions after these events.","PeriodicalId":504874,"journal":{"name":"ERJ Open Research","volume":"23 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141658920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-11DOI: 10.1183/23120541.00547-2024
E. Ben-Meir, Lina Antounians, Shafinaz Eisha, F. Ratjen, Augusto Zani, Hartmut Grasemann
The aim of this study was to quantify mediators of neutrophilic inflammation within airway extracellular vesicles (EVs) of children treated for a cystic fibrosis (CF) pulmonary exacerbation (PEx).EVs were isolated from stored sputum samples collected before and after antibiotic therapy for PEx between 2011–2013, and characterised by nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). Western blot analysis of EV protein extracts was used for EV canonical protein markers CD63, CD9, and flotillin-1 (FLOT1), as well as neutrophil elastase (NE), myeloperoxidase (MPO) and interleukin-8. EV content of NE and MPO was expressed as ratios of NE/FLOT1 and MPO/FLOT1 protein band densities.Sputum samples from 21 children aged 13.3 (range 8.0–17.0) years were analysed. NTA showed high concentrations of particles at the size of small EVs (50–200 nm), and typical EV morphology was confirmed by TEM. CD63, CD9 and FLOT1 was detectable in all samples. Median (IQR) NE/FLOT1 increased from 2.46 (1.68–5.25) before to 6.83 (3.89–8.89, p<0.001) after PEx therapy and MPO/FLOT1 from 2.30 (1.38–4.44) to 5.76 (3.45–6.94, p<0.01), while EV size remained unchanged. Improvement in lung function (ppFEV1) with PEx therapy correlated with NE EV content (r=0.657, p=0.001).Airways of children with CF contain EVs that carry NE and MPO as cargo. The lower NE and MPO content at the time of PEx compared to after therapy and the correlation with pulmonary function suggest both a functional role of EVs in CF airway inflammation and potential as a biomarker to monitor CF lung disease.
本研究旨在量化因囊性纤维化（CF）肺部恶化（PEx）而接受治疗的儿童气道细胞外囊泡（EV）中的中性粒细胞炎症介质。EV是从2011-2013年间因PEx而接受抗生素治疗前后收集的贮存痰液样本中分离出来的，并通过纳米颗粒追踪分析（NTA）和透射电子显微镜（TEM）对其进行了表征。对 EV 蛋白提取物进行了 Western 印迹分析，以检测 EV 的典型蛋白标记物 CD63、CD9、flotillin-1 (FLOT1)，以及中性粒细胞弹性蛋白酶 (NE)、髓过氧化物酶 (MPO) 和白细胞介素-8。NE和MPO的EV含量以NE/FLOT1和MPO/FLOT1蛋白条带密度的比率表示。NTA显示出高浓度的小EV颗粒（50-200 nm），TEM证实了典型的EV形态。所有样本均可检测到 CD63、CD9 和 FLOT1。PEx治疗后，NE/FLOT1的中位数（IQR）从治疗前的2.46（1.68-5.25）增加到6.83（3.89-8.89，p<0.001），MPO/FLOT1从2.30（1.38-4.44）增加到5.76（3.45-6.94，p<0.01），而EV的大小保持不变。PEx疗法对肺功能（ppFEV1）的改善与NE EV含量相关（r=0.657，p=0.001）。与治疗后相比，PEx治疗时的NE和MPO含量较低，且与肺功能相关，这表明EVs在CF气道炎症中发挥着功能性作用，并有可能成为监测CF肺部疾病的生物标记物。
{"title":"Extracellular vesicles in sputum of children with cystic fibrosis pulmonary exacerbations","authors":"E. Ben-Meir, Lina Antounians, Shafinaz Eisha, F. Ratjen, Augusto Zani, Hartmut Grasemann","doi":"10.1183/23120541.00547-2024","DOIUrl":"https://doi.org/10.1183/23120541.00547-2024","url":null,"abstract":"The aim of this study was to quantify mediators of neutrophilic inflammation within airway extracellular vesicles (EVs) of children treated for a cystic fibrosis (CF) pulmonary exacerbation (PEx).EVs were isolated from stored sputum samples collected before and after antibiotic therapy for PEx between 2011–2013, and characterised by nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). Western blot analysis of EV protein extracts was used for EV canonical protein markers CD63, CD9, and flotillin-1 (FLOT1), as well as neutrophil elastase (NE), myeloperoxidase (MPO) and interleukin-8. EV content of NE and MPO was expressed as ratios of NE/FLOT1 and MPO/FLOT1 protein band densities.Sputum samples from 21 children aged 13.3 (range 8.0–17.0) years were analysed. NTA showed high concentrations of particles at the size of small EVs (50–200 nm), and typical EV morphology was confirmed by TEM. CD63, CD9 and FLOT1 was detectable in all samples. Median (IQR) NE/FLOT1 increased from 2.46 (1.68–5.25) before to 6.83 (3.89–8.89, p<0.001) after PEx therapy and MPO/FLOT1 from 2.30 (1.38–4.44) to 5.76 (3.45–6.94, p<0.01), while EV size remained unchanged. Improvement in lung function (ppFEV1) with PEx therapy correlated with NE EV content (r=0.657, p=0.001).Airways of children with CF contain EVs that carry NE and MPO as cargo. The lower NE and MPO content at the time of PEx compared to after therapy and the correlation with pulmonary function suggest both a functional role of EVs in CF airway inflammation and potential as a biomarker to monitor CF lung disease.","PeriodicalId":504874,"journal":{"name":"ERJ Open Research","volume":"62 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141655373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-11DOI: 10.1183/23120541.00266-2024
I. Buendía-Roldán, L. Chávez-Galán, H. Aguilar-Duran, Andy Ruiz, R. Falfán-Valencia, G. Pérez-Rubio, A. Pardo, M. Selman
{"title":"Matrix metalloprotease-7 is associated with post-COVID persistent lung abnormalities.","authors":"I. Buendía-Roldán, L. Chávez-Galán, H. Aguilar-Duran, Andy Ruiz, R. Falfán-Valencia, G. Pérez-Rubio, A. Pardo, M. Selman","doi":"10.1183/23120541.00266-2024","DOIUrl":"https://doi.org/10.1183/23120541.00266-2024","url":null,"abstract":"","PeriodicalId":504874,"journal":{"name":"ERJ Open Research","volume":"86 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141657908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-11DOI: 10.1183/23120541.00416-2024
Jordan Jeffery, A. Vertigan, Sarah L. Bone, Peter G Gibson
Chronic refractory cough (CRC) is a challenging condition that responds to speech pathology intervention. Clinical observation suggests abnormal breathing patterns occur in CRC and may be indirectly addressed as part of behavioural treatment, yet breathing pattern changes in CRC are poorly understood. The aims of this study were to (1) describe breathing patterns in patients with CRC, (2) compare breathing pattern features between patients with CRC and inducible laryngeal obstruction (ILO), and (3) estimate the effect of breathing pattern features on clinical measures of laryngeal sensory and motor dysfunction.This retrospective cross sectional observational study included 634 patients with CRC or ILO. A file audit of speech pathology assessment data was undertaken. Analysis of self-reported laryngeal symptoms (viaquestionnaires) and clinical assessment of voice and breathing of those with CRC and ILO was conducted.Most participants with CRC (73%) demonstrated at least one abnormal breathing pattern feature. The most common feature was thoracic breathing (69%) followed by oral breathing (33%). The type and prevalence of abnormal breathing patterns were similar between CRC and ILO. Abnormal breathing patterns were associated with reduced maximum phonation time (MPT), however there was no association between these features and laryngeal hypersensitivity questionnaire scores.Abnormal breathing features are common in patients with CRC and are not significantly different from those occurring in ILO. There is some association between abnormal breathing features and MPT, suggesting impairment of laryngeal motor function. Conversely, there is no association between abnormal breathing features and laryngeal hypersensitivity.
{"title":"Abnormal breathing pattern features in chronic refractory cough","authors":"Jordan Jeffery, A. Vertigan, Sarah L. Bone, Peter G Gibson","doi":"10.1183/23120541.00416-2024","DOIUrl":"https://doi.org/10.1183/23120541.00416-2024","url":null,"abstract":"Chronic refractory cough (CRC) is a challenging condition that responds to speech pathology intervention. Clinical observation suggests abnormal breathing patterns occur in CRC and may be indirectly addressed as part of behavioural treatment, yet breathing pattern changes in CRC are poorly understood. The aims of this study were to (1) describe breathing patterns in patients with CRC, (2) compare breathing pattern features between patients with CRC and inducible laryngeal obstruction (ILO), and (3) estimate the effect of breathing pattern features on clinical measures of laryngeal sensory and motor dysfunction.This retrospective cross sectional observational study included 634 patients with CRC or ILO. A file audit of speech pathology assessment data was undertaken. Analysis of self-reported laryngeal symptoms (viaquestionnaires) and clinical assessment of voice and breathing of those with CRC and ILO was conducted.Most participants with CRC (73%) demonstrated at least one abnormal breathing pattern feature. The most common feature was thoracic breathing (69%) followed by oral breathing (33%). The type and prevalence of abnormal breathing patterns were similar between CRC and ILO. Abnormal breathing patterns were associated with reduced maximum phonation time (MPT), however there was no association between these features and laryngeal hypersensitivity questionnaire scores.Abnormal breathing features are common in patients with CRC and are not significantly different from those occurring in ILO. There is some association between abnormal breathing features and MPT, suggesting impairment of laryngeal motor function. Conversely, there is no association between abnormal breathing features and laryngeal hypersensitivity.","PeriodicalId":504874,"journal":{"name":"ERJ Open Research","volume":"99 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141657583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-11DOI: 10.1183/23120541.00288-2024
Esl Pedersen, M. Goutaki, L. Schreck, B. Rindlisbacher, L. Dixon, Jane S Lucas, C. Kuehni
{"title":"Questionnaire assessed genotypes and associations with symptoms in primary ciliary dyskinesia","authors":"Esl Pedersen, M. Goutaki, L. Schreck, B. Rindlisbacher, L. Dixon, Jane S Lucas, C. Kuehni","doi":"10.1183/23120541.00288-2024","DOIUrl":"https://doi.org/10.1183/23120541.00288-2024","url":null,"abstract":"","PeriodicalId":504874,"journal":{"name":"ERJ Open Research","volume":"78 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141655579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-04DOI: 10.1183/23120541.00154-2024
A. Ramírez-Venegas, F. Montiel-Lopez, R. Robles-Hernández, Bartolome R Celli, R. Sansores, Maricruz Cassou-Martínez, J. L. P. Lara-Albisua, Claudia González-González, M. E. Mayar-Maya, Aloisa P. Hernández-Morales, R. Hernández-Zenteno, R. Falfán-Valencia, Ireri Thirión-Romero, Oliver Pérez-Bautista, Rogelio Pérez-Padilla
Chronic obstructive pulmonary disease due to biomass exposure (COPD-B) is highly prevalent in low-and middle-income countries, and there are no clinical trials designed to evaluate the effectiveness of the treatments currently recommended for patients with COPD due to cigarette smoking (COPD-C). The purpose of the study was to compare the efficacy of Fluticasone Furoate/Vilanterol (FF/V) 100/25 μg and Umeclidinium/Vilanterol (U/V) 62.5/25 μg on the rate of exacerbations, the time to first exacerbation, on dyspnea, health-related quality of life (HRQL) and forced expiratory volume during the first second (FEV1) and inspiratory capacity (IC) during six months in patients with COPD-B and COPD-C, at a third level referral center in Mexico City.A pilot, single-center, open-label, parallel-group study included 132 patients with a history of at least two exacerbations. They were randomised to receive one of four treatment groups: 33 COPD-B patients received FF/VI 100/25 μg, 31 COPD-B patients received UMEC/VI 62.5/25 μg, 34 COPD-C patients received FF/V, and 34 received UMEC/VI.There were no differences in exacerbation rates between patients receiving FF/VI or UMEC/VI in either the COPD-B [0.07 (CI 95%, 0.03–0.13), 0.06 (CI 95%, 0.03–0.12] or COPD-C group [0.06 (CI 95%, 0.04–0.11); 0.08 (CI 95%, 0.05–0.13)], nor in the time of first exacerbation, nor FEV1and IC. All groups showed improvement in dyspnea and HRQL, independently of medication used.Among patients with COPD-B and COPD-C with a history of exacerbation, FF/VI was equally effective as UMEC/VI in preventing exacerbations and improving dyspnea and HRQL.
{"title":"Effectiveness of ICS/LABA and LAMA/LABA in COPD due to Biomass","authors":"A. Ramírez-Venegas, F. Montiel-Lopez, R. Robles-Hernández, Bartolome R Celli, R. Sansores, Maricruz Cassou-Martínez, J. L. P. Lara-Albisua, Claudia González-González, M. E. Mayar-Maya, Aloisa P. Hernández-Morales, R. Hernández-Zenteno, R. Falfán-Valencia, Ireri Thirión-Romero, Oliver Pérez-Bautista, Rogelio Pérez-Padilla","doi":"10.1183/23120541.00154-2024","DOIUrl":"https://doi.org/10.1183/23120541.00154-2024","url":null,"abstract":"Chronic obstructive pulmonary disease due to biomass exposure (COPD-B) is highly prevalent in low-and middle-income countries, and there are no clinical trials designed to evaluate the effectiveness of the treatments currently recommended for patients with COPD due to cigarette smoking (COPD-C). The purpose of the study was to compare the efficacy of Fluticasone Furoate/Vilanterol (FF/V) 100/25 μg and Umeclidinium/Vilanterol (U/V) 62.5/25 μg on the rate of exacerbations, the time to first exacerbation, on dyspnea, health-related quality of life (HRQL) and forced expiratory volume during the first second (FEV1) and inspiratory capacity (IC) during six months in patients with COPD-B and COPD-C, at a third level referral center in Mexico City.A pilot, single-center, open-label, parallel-group study included 132 patients with a history of at least two exacerbations. They were randomised to receive one of four treatment groups: 33 COPD-B patients received FF/VI 100/25 μg, 31 COPD-B patients received UMEC/VI 62.5/25 μg, 34 COPD-C patients received FF/V, and 34 received UMEC/VI.There were no differences in exacerbation rates between patients receiving FF/VI or UMEC/VI in either the COPD-B [0.07 (CI 95%, 0.03–0.13), 0.06 (CI 95%, 0.03–0.12] or COPD-C group [0.06 (CI 95%, 0.04–0.11); 0.08 (CI 95%, 0.05–0.13)], nor in the time of first exacerbation, nor FEV1and IC. All groups showed improvement in dyspnea and HRQL, independently of medication used.Among patients with COPD-B and COPD-C with a history of exacerbation, FF/VI was equally effective as UMEC/VI in preventing exacerbations and improving dyspnea and HRQL.","PeriodicalId":504874,"journal":{"name":"ERJ Open Research","volume":" 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141680725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：